Immunoglobulin Patents (Class 536/23.53)
  • ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES
    Publication number: 20140357844
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Shu-Hui LIU, Wei-Hsien HO, Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David Louis SHELTON, Thomas-Toan TRAN
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20140356355
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 4, 2014
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357854
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER
    Publication number: 20140348833
    Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
    Type: Application
    Filed: March 6, 2014
    Publication date: November 27, 2014
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
  • CHIMERIC THERAPEUTIC ANTI - CD37 ANTIBODIE HH1
    Publication number: 20140348745
    Abstract: The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 27, 2014
    Inventors: Roy H. Larsen, Jostein Dahle
  • NEUTRALIZING GP41 ANTIBODIES AND THEIR USE
    Publication number: 20140348785
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.
    Type: Application
    Filed: November 7, 2012
    Publication date: November 27, 2014
    Inventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
  • ANTIBODIES DIRECTED AGAINST INFLUENZA
    Publication number: 20140348851
    Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 27, 2014
    Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITY
    Inventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
  • BINDING MOLECULES FOR BCMA AND CD3
    Publication number: 20140348837
    Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 27, 2014
    Applicants: Amegen Research (Munich) GmbH, Boehringer Ingellheim iInternational Gmbh
    Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
  • COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL LESIONS
    Publication number: 20140348784
    Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ? (TNF?) or Tissue Factor protein (which may be truncated).
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Applicant: PHILOGEN S.P.A.
    Inventors: Luciano ZARDI, Dario NERI, Barbara CARNEMOLLA, Fredrik NILSSON, Lorenzo TARLI, Laura BORSI, Cornelia HALIN
  • INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140349342
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Application
    Filed: April 23, 2014
    Publication date: November 27, 2014
    Applicant: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • ANTI-GITR ANTIBODIES
    Publication number: 20140348841
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
  • MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY SCAFFOLDS
    Publication number: 20140348839
    Abstract: The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 27, 2014
    Inventors: Partha S. Chowdhury, Vaheh Oganesyan, Yariv Mazor, Nazzareno Dimasi
  • IMMUNOGLOBULINS WITH REDUCED AGGREGATION
    Publication number: 20140348820
    Abstract: The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.
    Type: Application
    Filed: April 29, 2014
    Publication date: November 27, 2014
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, NOVARTIS AG
    Inventors: Naresh CHENNAMSETTY, Bernhard HELK, Veysel KAYSER, Bernhardt TROUT, Vladimir VOYNOV
  • MONOCLONAL ANTIBODIES SPECIFIC FOR THE M2-1 ANTIGEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV)
    Publication number: 20140348858
    Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.
    Type: Application
    Filed: November 23, 2012
    Publication date: November 27, 2014
    Inventors: Alexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jorge Eugenio Mora Alarcon, Roberto Sebastian Gomez Johnson
  • OPTIMIZED MESSENGER RNA
    Publication number: 20140350089
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: March 3, 2014
    Publication date: November 27, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
  • COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES
    Publication number: 20140348859
    Abstract: Compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof are disclosed. The compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. Compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.
    Type: Application
    Filed: January 10, 2013
    Publication date: November 27, 2014
    Applicants: KONKUK UNIVERSITY, OMNI BIO PHARMACEUTICAL, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Soohyun Kim, Charles A. Dinarello, James D. Crapo
  • BINDING MOLECULES AGAINST DENGUE VIRUS AND USES THEREOF
    Publication number: 20140349321
    Abstract: The present invention relates to binding molecules suited to the diagnosis, prevention and/or treatment of dengue virus infection.
    Type: Application
    Filed: December 17, 2012
    Publication date: November 27, 2014
    Applicant: Agency for Science, Technology and Research
    Inventors: Katja Fink, Cheng-I Wang
  • Felinized Antibodies and Methods of Treating Retroviral Infections in Felines
    Publication number: 20140348829
    Abstract: Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
    Type: Application
    Filed: April 8, 2014
    Publication date: November 27, 2014
    Applicant: CYTODYN INC.
    Inventor: Richard Trauger
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20140349395
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Applicant: Apexigen, Inc.
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • sgp130/Fc dimers
    Patent number: 8895012
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: November 25, 2014
    Assignee: Conaris Research Institute AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • Biological products
    Patent number: 8895714
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Simon Peter Tickle, Heather Margaret Ladyman
  • VASCULAR ENDOTHELIAL GROWTH FACTOR 2
    Publication number: 20140342405
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
  • TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF
    Publication number: 20140343256
    Abstract: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody. It is further providing a pharmaceutical composition comprising said antibody, nucleic acid or vector and is directed to the use of said composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 20, 2014
    Applicant: Technische Universitaet Munchen
    Inventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
  • Human Rhinovirus (HRV) Antibodies
    Publication number: 20140341923
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventor: Po-Ying Chan-Hui
  • NOVEL ANTI-HUMAN CTGF ANTIBODY
    Publication number: 20140343258
    Abstract: [Problem] An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. [Means for Solution] An anti-human CTGF antibody includes: a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 10; and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 4.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 20, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
  • ANTIBODIES TO CCR2
    Publication number: 20140342450
    Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.
    Type: Application
    Filed: April 3, 2014
    Publication date: November 20, 2014
    Applicants: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina L. Liang
  • ANTI-PD-L1 ANTIBODIES AND USES THEREOF
    Publication number: 20140341917
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 20, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20140341892
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
  • HETERODIMERIC FC REGIONS, BINDING MOLECULES COMPRISING SAME, AND METHODS RELATING THERETO
    Publication number: 20140341906
    Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
  • IL-17 BINDING PROTEINS
    Publication number: 20140343267
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 20, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • BISPECIFIC ANTIBODY FRAGMENTS FOR NEUROLOGICAL DISEASE PROTEINS AND METHODS OF USE
    Publication number: 20140341907
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Application
    Filed: January 10, 2013
    Publication date: November 20, 2014
    Inventors: Michael Sierks, Yong Shen
  • BIOLOGICAL MATERIALS RELATED TO C-MET
    Publication number: 20140341903
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Application
    Filed: October 1, 2012
    Publication date: November 20, 2014
    Applicant: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF
    Publication number: 20140341929
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Application
    Filed: July 3, 2014
    Publication date: November 20, 2014
    Inventors: Ronald Vogels, Theodorus H.J. Kwaks
  • ANTI-HUMAN CD52 IMMUNOGLOBULINS
    Publication number: 20140341910
    Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
    Type: Application
    Filed: November 26, 2013
    Publication date: November 20, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
  • DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES
    Publication number: 20140342406
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • High affinity antibodies that neutralize enterotoxin B
    Patent number: 8889846
    Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: November 18, 2014
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 8889847
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: November 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140335014
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 8, 2014
    Publication date: November 13, 2014
    Applicant: AbbVie, Inc.
    Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
  • IL-17 BINDING PROTEINS
    Publication number: 20140335564
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 13, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20140336363
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140335091
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 13, 2014
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Alison Jane FORGIE, Javier Fernando CHAPARRO RIGGERS, Edward Roland LAVALLIE, Chia-Yang LIN, Lidia MOSYAK, Andrea ROSSI, Thomas John VAN BLARCOM
  • NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
    Publication number: 20140335101
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: February 27, 2014
    Publication date: November 13, 2014
    Applicant: Ablynx N.V.
    Inventor: Els Anna Alice Beirnaert
  • IN SILICO AFFINITY MATURATION
    Publication number: 20140335102
    Abstract: Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 13, 2014
    Applicant: Sanofi
    Inventors: Michael Oberlin, Romano Kroemer, Vincent Mikol, Hervé Minoux, Nicolas Baurin
  • Anti-cobra toxin antibody fragments and method of producing a VH library
    Patent number: 8883152
    Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof. There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama. These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: November 11, 2014
    Assignee: University of Guelph
    Inventors: J. Christopher Hall, Gabrielle Richard, Michael D. McLean
  • Humanized anti-CD19 antibodies
    Patent number: 8883992
    Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Medimmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • INFLUENZA HEMAGGLUTININ ANTIBODIES, COMPOSITIONS AND RELATED METHODS
    Publication number: 20140331366
    Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
  • HUMAN RHINOVIRUS (HRV) ANTIBODIES
    Publication number: 20140328797
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
  • AGR2 BLOCKING ANTIBODY AND USE THEREOF
    Publication number: 20140328829
    Abstract: Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 6, 2014
    Inventors: Dawei Li, Zhenghua Wu, Hao Guo, Qi Zhu, Dhahiri S. Mashausi
  • Monoclonal Antibody For The Detection of SNAP/CLIP Tag
    Publication number: 20140329253
    Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.
    Type: Application
    Filed: November 26, 2012
    Publication date: November 6, 2014
    Applicant: Fraunhofer-Gesllschaft zur Foerderung der angewandten Forschung e.V.
    Inventors: Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140328862
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 6, 2014
    Applicants: THE ROCKEFELLER UNIVERSITY, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin